Somatus
Runs value based care for kidney disease patients, paid to keep them off dialysis.
On the record
Checkpoint: Resolution of interim CEO situation (Larry Renfro listed as interim on team page)
The call
Somatus has scale and 100% retention in kidney value based care, but an unresolved CEO situation and an investor who could become a rival keep this unsettled.
Somatus manages care for about 500,000 kidney patients and makes money by preventing them from needing dialysis, the opposite of how traditional dialysis companies like DaVita and Fresenius make their profits. This creates a real advantage because the old dialysis companies earn more when patients stay sick longer, so they have less reason to prevent kidney failure. However, the company faces three big problems: no one knows for certain it can make money reliably (another company called Cano Health tried similar value-based care and stumbled), it has growing competitors like Strive and Monogram chasing the same patients, and its leadership is in transition. The one thing that could flip the picture overnight is UnitedHealth/Optum, which invests in Somatus but also competes in kidney care, if Optum decides to build or buy its own kidney-care program aggressively, Somatus's room to grow shrinks fast.
Why
01
AI pressure: None apparent. No AI product is running kidney risk prediction or care coordination in a way that has touched Somatus yet. Could AI do the core job? Unlikely.
02
Bigger players: UnitedHealth/Optum. Optum Ventures is both an investor and a vertically integrated care operator, so it could build or buy a competing kidney program instead of backing Somatus. Could a giant copy it? Probably.
03
What protects it. Deep clinical workflows and provider relationships built over 500,000 patients across all 50 states are hard to copy fast.
What would change this call
Somatus names a permanent CEO or announces a sale/acquisition within 12 months. Resolves whether the interim-CEO period reflects planned succession or distress.
Optum Ventures or UnitedHealth launches or acquires a competing kidney value-based care unit. Shows Somatus's investor turning into a direct competitor, compressing its market room.
CMS announces changes to ESRD Treatment Choices or Kidney Care Choices payment models. Would materially affect the revenue basis Somatus's contracts depend on.
Optum Ventures or UnitedHealth launches or acquires a competing kidney value-based care unit. Shows Somatus's investor turning into a direct competitor, compressing its market room.
CMS announces changes to ESRD Treatment Choices or Kidney Care Choices payment models. Would materially affect the revenue basis Somatus's contracts depend on.
Key numbers
- ~500,000 patients under active management
- >$14B in healthcare costs under management
- Valuation $2.5B at Series E, later secondary mark $4.98B
Named risks
- Unresolved CEO status, Interim President listed July 2026 versus founder CEO named as recently as January 2026.
- Heavy dependence on CMS and Medicare Advantage value-based payment models subject to policy change.
- Sector-wide fragile unit economics precedent set by Cano Health's February 2024 Chapter 11 filing.
- Headcount decline from 1,051 in 2023 to 959 by March 2026 per third-party workforce data.
- Crowded, similarly funded competitive field including Strive, InterWell, and Monogram alongside investor-competitor Optum.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Strive Health | contesting | Named as closest peer competitor in value-based kidney care by multiple trackers as of July 2026 |
| InterWell Health | gaining on | Backed by Fresenius after its 2022 Cricket Health acquisition; reported strong CMS quality scores June 10, 2026 |
| DaVita Kidney Care | contesting | Runs its own CMS value-based kidney program (CKCC), reported year-over-year gains March 18, 2026 |
| Fresenius Health Partners | contesting | Participates directly in the same CMS value-based kidney models as Somatus, per June 2026 reporting |
| Optum/UnitedHealth | gaining on | Holds a board seat via Optum Ventures while building its own vertically integrated value-based care ambitions |
| Monogram Health | contesting | Offers competing in-home care for chronic kidney disease and polychronic conditions as of 2026 |
Questions people ask
- Is Somatus profitable in 2026?
- Somatus discloses no audited revenue or profit figures. It claims 100% customer and provider partner retention in 2024 and YTD 2025 (July 22, 2025 press release) and manages over $14B in healthcare costs, but profitability itself remains unverified by any independent source.
- Who is Somatus's biggest competitor?
- Somatus competes most directly with Strive Health, InterWell Health, and Monogram Health in value-based kidney care, while dialysis incumbents DaVita Kidney Care and Fresenius Health Partners run their own competing CMS value-based kidney programs as of 2026.
- Could AI replace Somatus's business?
- AI could automate Somatus's RenalIQ risk-stratification analytics, which the company itself now brands 'AI-driven' (July 2025). But its in-home clinical care teams and multi-year payer risk contracts, built over roughly nine years, are not replaceable by software alone.
- Who owns Somatus?
- Somatus is privately held and venture-backed, with investors including Wellington Management, Optum Ventures, Deerfield Management, Elevance Health, Inova Health System, GIC, and Fidelity, per a February 28, 2022 Coverager report on its $325M Series E round.
- Is Somatus a unicorn?
- Yes. Somatus was valued above $2.5B at its Series E round closed February 23, 2022, according to FierceHealthcare, matching its listed unicorn status; a later unconfirmed secondary-market data point suggested a ~$4.98B valuation in June 2025.
- Has Somatus had layoffs?
- No layoff announcement has been publicly confirmed, but Revelio Labs workforce data show Somatus headcount fell from a 2023 peak of 1,051 to about 959 employees by March 2026, even as the company reported over 1,200 employees in November 2024.
Timeline
- 2026-07-20Company team page lists Larry Renfro as Interim President and CEO
- 2026-03Revelio Labs estimates headcount at 959, down from 2023 peak of 1,051
- 2026-01-22Press feature still names co-founder Dr. Ikenna Okezie as CEO
- 2025-07-22Somatus announces 500,000 patients under management and $14B costs managed
- 2025-06-27Secondary market data shows $300M round at ~$4.98B valuation (unconfirmed)
- 2024-11-20Company reports 34 states, over 1,200 employees
- 2024-08-06Somatus becomes first value-based kidney care provider with NCQA Health Equity Accreditation
- 2024-02Sun Life partnership announced for stop-loss kidney and cardiovascular care
- 2023-06Series F round of roughly $200M reported
- 2022-02-23Series E raises over $325M at valuation above $2.5B
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Somatus Surpasses 500,000 Patients Actively Under Management Across All 50 States and DC (2025-07-22)
- Collaboration Key to Tysons-Headquartered Somatus' Success (2024-11-20)
- Somatus Raises $11 Million in Series B Financing (2018-04)
- Somatus clinches $325M-plus series E to expand its value-based kidney care model (2022-02-23)
- Sell or Invest in Somatus Stock Pre-IPO (2026-07-07)
- Somatus IPO Timeline and Financing Details (2023-11-14)
- Somatus raises $325 million (2022-02-28)
- Somatus (Team page) (2026-07-20)
- How a Childhood Encounter with Racism Shaped Ikenna Okezie's Mission... (2026-01-22)
- Somatus Number of Employees 2026 (2026-03)
- Somatus Becomes First Value-based Kidney Care Management Provider to Receive NCQA Accreditation for Health Equ (2024-08-06)
- Somatus - Overview, News & Similar companies (2026-07-09)